Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 6/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359117 | 0.82 | KDM4E (0.34) | THRBTXNRD1GSREPHX2THRA | |
| SCHEMBL2245083 | 0.74 | SMPD3 (0.42) | IRAK4 | |
| SCHEMBL2322469 | 0.71 | THRB (0.34) | THRBEPHX2THRA | |
| SCHEMBL2319946 | 0.68 | ALOX5AP (0.35) | EPHX2 | |
| SCHEMBL1194725 | 0.66 | HTR6 (0.44) | — | |
| SCHEMBL3433516 | 0.66 | KDM4E (0.54) | — | |
| SCHEMBL2249258 | 0.65 | THRB (0.37) | THRBTXNRD1GSR | |
| SCHEMBL3468590 | 0.62 | DYRK1A (0.35) | THRBTXNRD1GSR | |
| SCHEMBL23728480 | 0.61 | NR4A3 (0.43) | IRAK4 | |
| SCHEMBL12360248 | 0.59 | FAAH (0.43) | THRBTXNRD1GSREPHX2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351756-A1 | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF | Ivashchenko, Andrey Alexandrovich (RU) | 2011-08-03 | — | — | EP | claimed |
| US-20110178078-A1 | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF | IVASHCHENKO ANDREY ALEXANDROVICH | 2011-07-21 | — | — | US | claimed |
| EP-3020719-A1 | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOFAND METHODS FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8618114-B2 | Substituted 3-arylsulfonyl-pyrazolo[1,5-A]pyrimidines, serotonin 5-HT6 receptor antagonists and methods for the production and use thereof | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2013-12-31 | — | — | US | disclosed |
| EP-2351756-A1 | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF | Ivashchenko, Andrey Alexandrovich (RU) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178078-A1 | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF | IVASHCHENKO ANDREY ALEXANDROVICH | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178078-A1 | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF | HTR6, HTR1A, HTR3A | THRB 711/4885TXNRD1 1606/4885GSR 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.